Deutsche Bank AG set a €106.00 ($123.26) price objective on Merck KGaA (FRA:MRK) in a research note issued to investors on Wednesday. The firm currently has a neutral rating on the healthcare company’s stock.

Other equities analysts also recently issued reports about the stock. BNP Paribas set a €114.00 ($132.56) target price on shares of Merck KGaA and gave the stock a buy rating in a report on Wednesday, May 10th. DZ Bank AG restated a neutral rating on shares of Merck KGaA in a report on Saturday, May 20th. equinet AG set a €91.00 ($105.81) target price on shares of Merck KGaA and gave the stock a neutral rating in a report on Saturday, May 20th. Warburg Research set a €116.00 ($134.88) target price on shares of Merck KGaA and gave the stock a neutral rating in a report on Tuesday, June 20th. Finally, Morgan Stanley set a €103.00 ($119.77) target price on shares of Merck KGaA and gave the stock a neutral rating in a report on Monday, May 15th. Two analysts have rated the stock with a sell rating, sixteen have given a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of Hold and a consensus target price of €109.55 ($127.38).

Merck KGaA (FRA:MRK) opened at 93.32 on Wednesday. The firm has a market capitalization of €40.52 billion and a price-to-earnings ratio of 26.02. The company has a 50-day moving average of €103.96 and a 200-day moving average of €104.56. Merck KGaA has a 1-year low of €89.00 and a 1-year high of €115.00.

TRADEMARK VIOLATION WARNING: This report was first reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://www.watchlistnews.com/deutsche-bank-ag-reiterates-106-00-price-target-for-merck-kgaa-framrk/1462017.html.

About Merck KGaA

.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with Analyst Ratings Network's FREE daily email newsletter.